Double-blind comparison of Hexabrix and Renografin-76 in computed tomography.
In a double-blind randomized assignment of Renografin-76 or Hexabrix, 65 patients were evaluated to determine the safety and efficacy of Hexabrix, and to assess subtle differences and their implications in image quality. Dosage was adjusted for patient weight, and up to 150-ml of Hexabrix or Renografin-76 were injected over a 2-minute period during which rapid sequence CT was performed. Less heat and discomfort were noted with Hexabrix. No difference was evidenced in the side effects of emesis or hives, and no real difference in renal dysfunction was noted from a clinical standpoint. Image quality was generally equivalent, with possibly better renal concentration achieved with Hexabrix.
D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000009:adverse effects; D003973:Diatrizoate / Q000009:adverse effects / Q000031:analogs & derivatives*; D003974:Diatrizoate Meglumine / Q000009:adverse effects; D004311:Double-Blind Method; D004338:Drug Combinations / Q000009:adverse effects; D005260:Female; D006801:Humans; D007463:Iodobenzoates; D007485:Ioxaglic Acid; D008875:Middle Aged; D014057:Tomography, X-Ray Computed / Q000009:adverse effects; D014283:Triiodobenzoic Acids / Q000009:adverse effects
D003287:Contrast Media; D004338:Drug Combinations; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D003973:Diatrizoate; D003974:Diatrizoate Meglumine; C027278:urovision; D007485:Ioxaglic Acid